Current Report Filing (8-k)
December 07 2020 - 8:01AM
Edgar (US Regulatory)
0001629137 False 0001629137 2020-12-06 2020-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): December 6,
2020
_______________________________
Global
Blood Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
_______________________________
Delaware
|
001-37539
|
27-4825712
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
181
Oyster Point Blvd.
South
San Francisco, California
94080
(Address of Principal Executive Offices) (Zip Code)
(650)
741-7700
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since
last report)
_______________________________
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common Stock, par value $0.001
per share
|
GBT
|
The
NASDAQ Global Select Market
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On December 6, 2020, Global Blood Therapeutics, Inc.
issued two press releases titled “GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta®
(voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition” and “GBT
Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and
GBT021601.” Copies of the press releases are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on
Form 8-K and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
Global Blood Therapeutics, Inc.
|
|
|
|
|
|
|
Date: December 7, 2020
|
By:
|
/s/ Jeffrey Farrow
|
|
|
Jeffrey Farrow
|
|
|
Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024